Testing new drug combos for HER2-positive breast cancer not responding to first therapy
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have early stage HER2-positive breast cancer (the kind that makes extra HER2 protein) that has not spread far beyond the breast or nearby lymph nodes.
- Your tumor is larger than 1 cm (about the size of a pea).
- You have already received at least 2 cycles of standard dual HER2-targeted therapy with chemotherapy, but your tumor did not shrink enough.
- You have good organ function (heart, liver, kidneys) and are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different treatments for women with HER2-positive early breast cancer who had a complete response to initial therapy but still have cancer DNA in their blood. It aims to see which treatment is better at preventing the cancer from coming back.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial compares two different chemotherapy combinations (one with a newer type of paclitaxel called polymeric micelles, plus an immunotherapy drug called adebelimab) against a standard taxane plus HP regimen, as first-line treatment for advanced HER2-positive breast cancer. The goal is to see if the new combination works better at controlling the cancer.
This trial tests a combination of two targeted drugs (SHR-A1811 and pertuzumab) given before surgery to shrink HER2-positive breast cancer. It aims to see if this approach improves outcomes for patients with early-stage but high-risk disease.
This study tests a personalized treatment approach for HER2-positive breast cancer. It uses regular monitoring of your tumor to adjust the treatment before surgery, aiming to improve results. It might help you by tailoring therapy to your cancer's response.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
Hear when a new HER2-positive Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.